Will long-term consumption of deuterated colexitinib/sondido affect fertility function?

Deucravacitinib is a new generation of oral small molecule targeted drugs approved in recent years. It is mainly used for the treatment of moderate to severe plaque psoriasis. It intervenes in the immune response by selectively inhibiting the TYK2 pathway. Compared with traditional immunosuppressants, it has higher targeting and lower risk of widespread immunosuppression.

From the perspective of pharmacological mechanism, deuterated colexitinib is not a drug that directly acts on the reproductive system or hormone secretion pathways, but selectively interferes with inflammatory signaling. Therefore, current data do not show a direct correlation with decreased fertility.

However, psoriasis itself is a chronic inflammatory disease. If not well controlled, it may indirectly affect the patient's desire and ability to have children through chronic inflammatory state, systemic immune activation and psychological stress. By effectively treating diseases, in a sense, it helps to improve overall health and quality of life, thereby indirectly benefiting fertility.

On the other hand, long-term use of any immunomodulatory drug requires attention to the impact on the body's overall balance. Overseas academic institutions have suggested that patients planning to become pregnant should fully communicate with their doctors before using such drugs, and develop a reasonable discontinuation or transition plan based on their condition and drug half-life to avoid potential risks. Although there is currently a lack of evidence regarding the adverse effects of deuterated colexitinib on male sperm quality or female ovarian function, for safety reasons, most clinicians would recommend suspending or switching to a suitable alternative treatment during planned pregnancy.

To sum up, long-term use of deuterated colexitinib has not been proven to directly damage fertility function. However, since the accumulation of data is still limited, it is recommended that patients who have fertility plans should adjust their medication under the guidance of a doctor, combined with regular physical examinations and disease assessment, to ensure that a balance between disease control and future fertility needs is found.

Reference materials:https://go.drugbank.com/drugs/DB16650